Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 09, 2020 16:08 ET | Source: Aptinyx Inc.

Aptinyx Announces Proposed Public Offering of Common Stock

EVANSTON, Ill., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
December 12, 2019 07:07 ET | Source: Aptinyx Inc.

Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference

EVANSTON, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
December 05, 2019 06:58 ET | Source: Aptinyx Inc.

Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson’s Disease

Phase 2 study follows NYX-458 preclinical data demonstrating reversal of cognitive deficits in non-human primate model of Parkinson’s disease Fourth Phase 2 study initiated by Aptinyx in 2019 across...
October 28, 2019 07:57 ET | Source: Aptinyx Inc.

Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting

Study met primary and secondary endpoints – statistically significant effects on neuroimaging biomarkers and patient-reported measures ePoster to be presented at ACR Annual Meeting on Tuesday,...
September 23, 2019 17:27 ET | Source: Schall Law

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, Sept. 23, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aptinyx Inc....
September 04, 2019 07:27 ET | Source: Aptinyx Inc.

Former Principal Deputy Commissioner of FDA, Dr. Rachel Sherman, Joins Aptinyx Board of Directors

EVANSTON, Ill., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
August 21, 2019 08:33 ET | Source: Aptinyx Inc.

Aptinyx Presents Data Demonstrating Positive Activity of NYX-458 on Cognitive Performance and Biomarkers in a Preclinical Model of Head Injury

EVANSTON, Ill., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
August 12, 2019 06:33 ET | Source: Aptinyx Inc.

Aptinyx Reports Second Quarter 2019 Financial Results and Highlights

Reported that NYX-2925 met primary and secondary endpoints in Phase 2 fibromyalgia study On track to initiate three additional Phase 2 studies in 2H 2019 across pipeline of CNS product candidates ...
August 06, 2019 08:33 ET | Source: Aptinyx Inc.

Aptinyx to Present at the 2019 Wedbush PacGrow Healthcare Conference

EVANSTON, Ill., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
June 26, 2019 08:03 ET | Source: Aptinyx Inc.

Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior and Relapse-Like Behavior in Multiple Models of Alcohol Use Disorder

EVANSTON, Ill., June 26, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...

Next Page keyboard_arrow_right